Last reviewed · How we verify
Lipid Modifying Therapy (LMT)
Lipid Modifying Therapy reduces circulating lipid levels through modulation of lipid metabolism pathways to lower cardiovascular risk.
Lipid Modifying Therapy reduces circulating lipid levels through modulation of lipid metabolism pathways to lower cardiovascular risk. Used for Hyperlipidemia / dyslipidemia, Cardiovascular disease prevention.
At a glance
| Generic name | Lipid Modifying Therapy (LMT) |
|---|---|
| Sponsor | Sanofi |
| Drug class | Lipid-lowering agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
LMT encompasses various pharmacological approaches to alter lipid profiles, typically targeting cholesterol synthesis, lipoprotein metabolism, or lipid absorption. The specific mechanism depends on the active agent within the therapy class, which may include inhibition of key enzymes in cholesterol biosynthesis or enhancement of lipid clearance pathways.
Approved indications
- Hyperlipidemia / dyslipidemia
- Cardiovascular disease prevention
Common side effects
- Muscle pain or myalgia
- Elevated liver enzymes
- Gastrointestinal disturbances
Key clinical trials
- Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography (NA)
- Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia (PHASE2)
- Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE) (PHASE3)
- Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE) (PHASE3)
- Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II) (PHASE3)
- Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia (PHASE3)
- Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy (PHASE3)
- An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipid Modifying Therapy (LMT) CI brief — competitive landscape report
- Lipid Modifying Therapy (LMT) updates RSS · CI watch RSS
- Sanofi portfolio CI